Use of hypericum as antidepressant

BMJ 2000; 320 doi: http://dx.doi.org/10.1136/bmj.320.7242.1141/a (Published 22 April 2000)
Cite this as: BMJ 2000;320:1141.2

Get access to this article and all of bmj.com for the next 14 days

Sign up for a 14 day free trial today

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

Valid measure of antidepressant efficacy in primary care is needed

  1. Andrew Thornett, clinical research fellow (eanador@soton.ac.uk)
  1. Department of Psychiatry, University of Southampton, Southampton SO9 5NH
  2. Harvey Group Practice, St Albans AL3 5HB
  3. Integrative Medicine Service, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
  4. Arlington, Texas 76012-4704, USA
  5. Dunedin Hospital, Dunedin, New Zealand
  6. West Cumberland Hospital, Whitehaven, Cumbria CA28 8JG
  7. Bezirkskrankenhaus Landshut, D-84034 Landshut, Germany
  8. Imerem Institute for Medical Research Management and Biometrics, D-90478 Nuremberg, Germany
  9. Steiner Arzneimittel, D-12207 Berlin, Germany

    EDITOR—The study by Philipp et al comparing hypericum extract and imipramine or placebo seems to show that hypericum is as effective at treating moderate depression as imipramine.1 This impression is strengthened by the design of the study, which is double blind, randomised, and placebo controlled, using a widely used medication as a comparator and using globally accepted depression scales including the Hamilton depression score. Linde and Berner, however, in the accompanying commentary question the efficacy of hypericum because of its use in comparatively large doses and its comparison with low doses of standard antidepressants.1 They believe that these, together with the effect of unblinding on outcome, should be taken into account in the analysis of the results. The basis of this criticism is the lack of universal consensus on how the effects of antidepressant drugs should be measured in primary care. Difficulty arises because lower doses are often used to treat patients who may be less depressed than those seen in secondary care, and the treatments themselves may be more important as an adjunct to the interaction between doctor and patient than as a therapeutic intervention alone. Patients, too, may prefer to use treatment options that they see as more natural, including hypericum, and doctors are beginning to accept the importance of supporting patients' choices.2 Linde and Berne do not consider that most general practitioners use 20 mg of fluoxetine when treating depressed patients, and few are prepared to increase the dose beyond this level. This reluctance is less likely to be present with a treatment that is seen as part of alternative medicine and less likely to produce side effects.

    Further, in practice both patients and doctors know which medication has been prescribed, and the pragmatic nature of the trial conducted by Philipp et al reflects …

    Get access to this article and all of bmj.com for the next 14 days

    Sign up for a 14 day free trial today

    Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    THIS WEEK'S POLL